Syros An expression makes a world of difference

Syros’s Vision for Tamibarotene is to be the Foundation of Care for RARA-positive Patients

Tamibarotene (formerly SY-1425) is an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist that we are developing for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. We are currently investigating tamibarotene in our SELECT-MDS (Phase 3) trial in RARA-positive patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

Access the on-demand replay of our symposium at MDS 2021 to learn more.

This session is not included in the main conference CME/CPD credit.

WATCH THE SYMPOSIUM

Data from an earlier, now fully enrolled Phase 2 study showed that tamibarotene in combination with azacitidine had high response rates, rapid onset of responses, and clinically meaningful durability in RARA-positive newly diagnosed AML patients who are not suitable candidates for standard chemotherapy. The data also showed that tamibarotene in combination with azacitidine was generally well-tolerated with no increase in toxicities beyond what has been previously seen with either agent alone.

 

Approximately 30% of people with MDS have overexpression of the RARA gene.

30% of people with MDS have overexperssion of the RARA gene

NOW ENROLLING PHASE 3 TRIAL SELECT-MDS:

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Click to view study details and site locations.

Follow our progress Syros.com
Twitter Linked In

Tamibarotene is an investigational agent and has not been approved by the FDA as a treatment for any indication.

Unsubscribe